Quality Policy
At ETTERNITY DERMAL, S.L., the company responsible for the PRESSENSA brand, our mission is to offer professional medical aesthetic transdermal products under the strictest standards of safety and efficacy. Our quality strategy is based on a combination of advanced science, continuous innovation, and a firm commitment to customer satisfaction.
1. Commitment to Excellence
We are committed to researching, developing, and manufacturing highly effective cosmetic products and medical devices formulated with high-purity active ingredients of the highest quality. Inspired by nature and technology, our products guarantee visible and safe results for aesthetic professionals.
2. Regulatory Compliance
Our Quality Management System complies with international standards ISO 9001 and ISO 13485 and is complemented by Good Manufacturing Practices (ISO 22716), ensuring control and traceability across all production processes.
3. Patient Safety and Traceability
All our products undergo strict quality controls, including electronic verification, on-site testing, and documented monitoring, ensuring full traceability from raw material to end user.
4. Professional Customer Focus
We design solutions that respond to the real needs of aesthetic clinics and industry professionals. We maintain open communication channels to receive feedback and effectively respond to their expectations and suggestions.
5. Continuous Improvement
We systematically review our processes, key performance indicators (KPIs), and quality objectives. Ongoing team training and periodic system reviews are fundamental pillars of continuous improvement.
6. Shared Responsibility
All members of the ETTERNITY DERMAL, S.L. team are committed to quality. They receive appropriate training, assume specific responsibilities, and work in coordination to achieve the objectives defined by Management and the Quality Manager.
7. Review and Communication
This policy is reviewed annually by Management and is available on our website. Its proper implementation is continuously monitored to ensure its effectiveness and alignment with the organizational context.
Approved by:
Quality Director
Date: June 25, 2025
